Literature DB >> 9840448

Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia.

A E Pontiroli1, L Galli.   

Abstract

Obesity is often accompanied by non-insulin-dependent diabetes mellitus (type 2), arterial hypertension, and hyperlipidaemia. The aim of this study was to evaluate whether duration of obesity is a risk factor for the appearance of type 2 diabetes, hypertension, and hyperlipidaemia. We studied 760 obese subjects, 207 of whom had normal glucose tolerance, 125 impaired glucose tolerance, and 428 type 2 diabetes; in addition, 560 had hypertension and 315 had hyperlipidaemia. At univariate analysis, passing from normal through impaired glucose tolerance to type 2 diabetes there was a progressive increase of age and of duration of obesity, hypertension and hyperlipidaemia. Compared to subjects without hypertension, hypertensive subjects were older, had a longer duration of obesity, a greater body mass index (BMI, kg/m2), and more frequently a family history of hypertension; they also more frequently showed impaired glucose tolerance and type 2 diabetes and hyperlipidaemia. Compared to subjects without hyperlipidaemia, hyperlipidaemic subjects were older, had a longer duration of obesity, and more frequently showed impaired glucose tolerance and type 2 diabetes, and hypertension. Diabetes, hypertension, and hyperlipidaemia were highly associated, as up to 80% of subjects with type 2 diabetes had hypertension, and more than 80% of hyperlipidaemic subjects had hypertension. Type 2 diabetes was less frequent than hypertension and hyperlipidaemia during the first 10 years of obesity, and progressively increased thereafter; in contrast the frequency of hypertension and of hyperlipidaemia increased only after 30 years of obesity. In 359 subjects undergoing an oral glucose tolerance test (168 with simultaneous determination of insulin release), increasing durations of obesity were accompanied by an increasing prevalence of type 2 diabetes, and in deterioration of glucose response, with no decrease in insulin release. At logistic regression analysis, age was a common risk factor for diabetes, hypertension, and hyperlipidaemia; duration of obesity and hyperlipidaemia were additional risk factors for diabetes; family history of hypertension, BMI and hyperlipidaemia were additional risk factors for hypertension, as were impaired glucose tolerance or diabetes, and hypertension for hyperlipidaemia. These data indicate that duration of obesity is a risk factor for type 2 diabetes, and emphasize the importance of preventing obesity in young subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840448     DOI: 10.1007/s005920050117

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  19 in total

Review 1.  Dietary diversity score and obesity: a systematic review and meta-analysis of observational studies.

Authors:  A Salehi-Abargouei; F Akbari; N Bellissimo; L Azadbakht
Journal:  Eur J Clin Nutr       Date:  2015-07-29       Impact factor: 4.016

2.  Duration and degree of adiposity: effect on cardiovascular risk factors at early adulthood.

Authors:  J Araújo; M Severo; H Barros; E Ramos
Journal:  Int J Obes (Lond)       Date:  2017-06-06       Impact factor: 5.095

Review 3.  Paediatric obesity and cardiovascular risk factors - A life course approach.

Authors:  Joana Araújo; Elisabete Ramos
Journal:  Porto Biomed J       Date:  2017-03-17

4.  Association between obesity history and hand grip strength in older adults--exploring the roles of inflammation and insulin resistance as mediating factors.

Authors:  Sari Stenholm; Janne Sallinen; Annemarie Koster; Taina Rantanen; Päivi Sainio; Markku Heliövaara; Seppo Koskinen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-02-10       Impact factor: 6.053

5.  Evidence for Association between SH2B1 Gene Variants and Glycated Hemoglobin in Nondiabetic European American Young Adults: The Add Health Study.

Authors:  Leslie A Lange; Mariaelisa Graff; Ethan M Lange; Kristin L Young; Andrea S Richardson; Karen L Mohlke; Kari E North; Kathleen M Harris; Penny Gordon-Larsen
Journal:  Ann Hum Genet       Date:  2016-09       Impact factor: 1.670

6.  Association of obesity and type II diabetes mellitus as a risk factor for gallstones.

Authors:  M Pacchioni; C Nicoletti; M Caminiti; G Calori; V Curci; R Camisasca; A E Pontiroli
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

7.  Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study.

Authors:  Danielle R Bouchard; Bianca Porneala; Ian Janssen; Marie-France Langlois; Jean-Patrice Baillargeon; Caroline S Fox; James B Meigs; Ralph B D'Agostino; Michael Pencina; Marie-France Hivert
Journal:  J Diabetes Complications       Date:  2013-01-10       Impact factor: 2.852

8.  Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age.

Authors:  Jared P Reis; Catherine M Loria; Cora E Lewis; Tiffany M Powell-Wiley; Gina S Wei; J Jeffrey Carr; James G Terry; Kiang Liu
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

9.  The effect of obesity in adolescence on adult health status.

Authors:  Thomas H Inge; Wendy C King; Todd M Jenkins; Anita P Courcoulas; Mark Mitsnefes; David R Flum; Bruce M Wolfe; Alfons Pomp; Greg F Dakin; Saurabh Khandelwal; Meg H Zeller; Mary Horlick; John R Pender; Jia-Yuh Chen; Stephen R Daniels
Journal:  Pediatrics       Date:  2013-11-18       Impact factor: 7.124

10.  Nicotinamide attenuates streptozotocin-induced diabetes complications and increases survival rate in rats: role of autonomic nervous system.

Authors:  Paula L Cruz; Ivana C Moraes-Silva; Amanda A Ribeiro; Jacqueline F Machi; Marcelo Dantas Tavares de Melo; Fernando Dos Santos; Maikon Barbosa da Silva; Celia Maria Cassaro Strunz; Elia Garcia Caldini; Maria-Claudia Irigoyen
Journal:  BMC Endocr Disord       Date:  2021-06-28       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.